Resverlogix Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RVXCF research report →
Price Chart
About the company
Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalone (RVX-208), a selective small molecule designed to inhibit bromodomain and extra-terminal proteins. This compound is presently undergoing pivotal Phase III clinical trials for patients afflicted with conditions such as cardiovascular disease, diabetes, various stages of kidney disease (including end-stage renal disease), and neurodegenerative disorders.
- CEO
- Donald J. McCaffrey
- IPO
- 2009
- Employees
- 19
- HQ
- Calgary, AB, CA
Get TickerSpark's AI analysis on RVXCF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $17.21M
- P/E
- -1.62
- PEG
- 0.09
- P/S
- 0.00
- P/B
- -0.19
- EV/EBITDA
- -17.39
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 11.24%
- ROIC
- 35.51%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-437,527-32.1%
- Op Income
- $-5,203,523
- Net Income
- $-7,902,965-3.5%
- EPS
- $-0.03-0.4%
- OCF Growth
- +4.1%
- FCF Growth
- +14.3%
- 52W High
- $0.10
- 52W Low
- $0.04
- 50D MA
- $0.06
- 200D MA
- $0.07
- Beta
- 1.05
- RSI (14)
- 39
- Avg Volume
- 12.48K
No earnings-call transcripts are available for RVXCF yet.
- Free Float
- 73.0%
- Shares Outstanding
- 344.29M
- Float Shares
- 251.22M
Our RVXCF coverage
Recent articles, reports, and earnings notes.
No research on RVXCF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RVXCF report →Resverlogix Closes US$2 Million Shares-for-Interest Private Placement
newsfilecorp.com · May 19
Resverlogix Announces One-Year Extension of Debenture
newsfilecorp.com · May 11
Resverlogix Corp. Announces Filing of Annual Filings and Revocation of MCTO
newsfilecorp.com · Apr 16
Resverlogix Corp. Announces Issuance of MCTO by ASC
newsfilecorp.com · Apr 2
Resverlogix Corp. Provides Bi-Weekly MCTO Status Update
newsfilecorp.com · Mar 31
Resverlogix Announces Delay in Filing of Annual Financial Statements, AIF, and MD&A
newsfilecorp.com · Mar 17
Resverlogix Closes $2.8 Million Shares-for-Interest Private Placement
newsfilecorp.com · Feb 18
Resverlogix Appoints Bradley Glass to Board of Directors
newsfilecorp.com · Nov 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.